Neugranin (balugrastim biosimilar) - Teva
Teva: Q3 2014 Results (Teva) - Nov 9, 2014 - “…development of balugrastim… for the U.S. and the EU markets, will be terminated by the end of 2014” 
Anticipated discontinuation • Biosimilar
http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-EventDetails&EventId=5170819
 
Nov 9, 2014
 
.
 
9cdf24c5-ac0b-4661-a23c-8319b162ffed.jpg